

# ForPatients

by Roche

Breast Cancer Er-Positive Breast Cancer HER-2 Negative Locally Advanced or Metastatic Breast Cancer Breast Cancer Estrogen Receptor (ER)-Positive

## A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

**Trial Status**  
Recruiting

**Trial Runs In**  
13 Countries

**Trial Identifier**  
NCT05306340  
2022-000199-20,2023-506821-12-00  
ML43171

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.

**Genentech, Inc.**  
Sponsor

**Phase 3**  
Phase

---

**NCT05306340 2022-000199-20,2023-506821-12-00 ML43171**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---